<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:34:55Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7736887" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7736887</identifier>
        <datestamp>2020-12-15</datestamp>
        <setSpec>scirep</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
              <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
              <journal-title-group>
                <journal-title>Scientific Reports</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2045-2322</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7736887</article-id>
              <article-id pub-id-type="pmcid">PMC7736887</article-id>
              <article-id pub-id-type="pmc-uid">7736887</article-id>
              <article-id pub-id-type="pmid">33318514</article-id>
              <article-id pub-id-type="publisher-id">78865</article-id>
              <article-id pub-id-type="doi">10.1038/s41598-020-78865-3</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Evaluation of primary breast cancers using dedicated breast PET and whole-body PET</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hathi</surname>
                    <given-names>Deep K.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Wen</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Seo</surname>
                    <given-names>Youngho</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Flavell</surname>
                    <given-names>Robert R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kornak</surname>
                    <given-names>John</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Franc</surname>
                    <given-names>Benjamin L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Joe</surname>
                    <given-names>Bonnie N.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Esserman</surname>
                    <given-names>Laura J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hylton</surname>
                    <given-names>Nola M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Jones</surname>
                    <given-names>Ella F.</given-names>
                  </name>
                  <address>
                    <email>ella.jones@ucsf.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution>Department of Radiology and Biomedical Imaging, </institution><institution>University of California, </institution></institution-wrap>San Francisco, CA USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution>Department of Epidemiology and Biostatistics, </institution><institution>University of California, </institution></institution-wrap>San Francisco, CA USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Department of Radiology, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution>Department of Surgery and Carol Franc Buck Breast Care Center, </institution><institution>University of California, </institution></institution-wrap>San Francisco, CA USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>14</day>
                <month>12</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>14</day>
                <month>12</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2020</year>
              </pub-date>
              <volume>10</volume>
              <elocation-id>21930</elocation-id>
              <history>
                <date date-type="received">
                  <day>18</day>
                  <month>5</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>17</day>
                  <month>11</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2020</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">Metabolic imaging of the primary breast tumor with <sup>18</sup>F-fluorodeoxyglucose ([<sup>18</sup>F]FDG) PET may assist in predicting treatment response in the neoadjuvant chemotherapy (NAC) setting. Dedicated breast PET (dbPET) is a high-resolution imaging modality with demonstrated ability in highlighting intratumoral heterogeneity and identifying small lesions in the breast volume. In this study, we characterized similarities and differences in the uptake of [<sup>18</sup>F]FDG in dbPET compared to whole-body PET (wbPET) in a cohort of ten patients with biopsy-confirmed, locally advanced breast cancer at the pre-treatment timepoint. Patients received bilateral dbPET and wbPET following administration of 186 MBq and 307 MBq [<sup>18</sup>F]FDG on separate days, respectively. [<sup>18</sup>F]FDG uptake measurements and 20 radiomic features based on morphology, tumor intensity, and texture were calculated and compared. There was a fivefold increase in SUL<sub>peak</sub> for dbPET (median difference (95% CI): 4.0 mL<sup>−1</sup> (1.8–6.4 mL<sup>−1</sup>), <italic>p</italic> = 0.006). Additionally, spatial heterogeneity features showed statistically significant differences between dbPET and wbPET. The higher [<sup>18</sup>F]FDG uptake in dbPET highlighted the dynamic range of this breast-specific imaging modality. Combining with the higher spatial resolution, dbPET may be able to detect treatment response in the primary tumor during NAC, and future studies with larger cohorts are warranted.</p>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Biomarkers</kwd>
                <kwd>Medical research</kwd>
                <kwd>Cancer</kwd>
                <kwd>Breast cancer</kwd>
                <kwd>Cancer imaging</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id>
                      <institution>U.S. Department of Defense</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>BC171237</award-id>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id>
                      <institution>National Institutes of Health</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01CA227763</award-id>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001252</institution-id>
                      <institution>Mount Zion Health Fund</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>20160729 [CA-0097143])</award-id>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>Give Cancer the Boot Fund</institution>
                  </funding-source>
                  <award-id>7028391</award-id>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>UCSF Breast Oncology Program</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par2">Breast cancer is a heterogeneous disease defined by the underlying genomic and proteomic expression profiles that affect treatment outcomes, recurrence risk, and response to therapy<sup><xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR4">4</xref></sup>. The identification of the four primary subtypes has enabled increasingly personalized treatment tailored to the molecular signature of breast cancers, resulting in improved prognoses and quality of life<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>. In particular, imaging of the primary tumor may provide critical predictive information for early response to targeted systemic therapies in patients receiving neoadjuvant chemotherapy (NAC)<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>.</p>
              <p id="Par3">Uptake of the glucose analog <sup>18</sup>F-fluorodeoxyglucose ([<sup>18</sup>F]FDG) in tumor tissues provides an opportunity to assess the tumor’s viability and glycolytic potential. Whole-body positron emission tomography (wbPET) with [<sup>18</sup>F]FDG is the primary tool for disease staging, with demonstrated sensitivity in detecting early response to NAC<sup><xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR12">12</xref></sup>. However, the effectiveness of wbPET in the quantitative measurement of [<sup>18</sup>F]FDG uptake in primary breast tumors is hampered due to significant partial volume effects caused by limited spatial resolution, especially in small tumors<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>. Additionally, wbPET is primarily performed with the patient in a supine position, resulting in the collapse of the breast volume and blurring due to respiratory motion<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. A complementary method for functional 3D imaging of the primary breast tumor is the use of dedicated breast PET (dbPET)<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>.</p>
              <p id="Par4">Studies with [<sup>18</sup>F]FDG-dbPET have qualitatively demonstrated its improved spatial resolution and uptake sensitivity within the primary tumor, at the expense of not being able to image metastatic lesions<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. Compared to wbPET-CT, dbPET may also provide an opportunity for longitudinal imaging using a lower dose of the radiotracer (185 vs. 370 MBq) and lower radiation exposure without CT. The dbPET scanner in the current study consists of a single ring detector that translates axially over the length of the breast<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. Because the patient is in a prone position, there is no breast compression, allowing for full breast volume imaging. We have also previously demonstrated this system's robustness for experimental imaging tracers, such as the radiotracer <sup>18</sup>F-fluoroestradiol in a pilot study of estrogen receptor-positive breast cancer patients<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. However, there is a need for validating the uptake, and tumor volume measurements generated from dbPET against the standard, clinically recognized wbPET. In this study, we assessed [<sup>18</sup>F]FDG uptake in pre-treatment breast cancer patients that received both dbPET and wbPET to characterize the similarities and differences in standard descriptive metrics, including standardized uptake values (SUVs), metabolic measures, and spatial heterogeneity statistics.</p>
            </sec>
            <sec id="Sec2">
              <title>Results</title>
              <sec id="Sec3">
                <title>Patient and tumor characteristics</title>
                <p id="Par5">This cohort consisted of ten patients with biopsy-confirmed, locally advanced, stage II-III invasive ductal carcinoma (Table <xref rid="Tab1" ref-type="table">1</xref>). Patients in the study cohort had a median age of 46.5 with an interquartile range (IQR) of 39.3–57.8. 60% of the patients were pre-menopausal (≤ 50 years, N = 6), and 40% were post-menopausal (&gt; 50 years, N = 4). Based on the hormone receptor (estrogen receptor (ER), progesterone receptor (PR)), and human epidermal growth factor receptor 2 (HER2) status, the primary breast tumors (N = 10) were mostly hormonal positive (ER+/PR+/HER2+ and ER+/PR+/HER2−, N = 6, 60%) and triple-negative (ER−/PR−/HER2−, N = 3, 30%). The median longest diameter measured by magnetic resonance imaging (MRI) was 3.4 cm (IQR 2.4–5.6 cm). The majority of patients (80%, N = 8) also had positive nodal involvement.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of patient and tumor characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Value</th></tr></thead><tbody><tr><td align="left">Number of patients (N)</td><td align="left">10</td></tr><tr><td align="left" colspan="2"><bold>Tumor characteristics</bold></td></tr><tr><td align="left">Number of unique tumors (N)</td><td align="left">10</td></tr><tr><td align="left">Longest diameter by MRI (cm) [median (interquartile range)]</td><td align="left">3.4 (2.3–5.6)</td></tr><tr><td align="left">Stage II (N)</td><td align="left">6</td></tr><tr><td align="left">Stage III (N)</td><td align="left">4</td></tr><tr><td align="left">Age (years) [median (interquartile range)]</td><td align="left">46.5 (39.3–57.8)</td></tr><tr><td align="left">Body weight (kg) [median (interquartile range)]</td><td align="left">66.6 (63.0–68.2)</td></tr><tr><td align="left" colspan="2"><bold>Menopause status (N)</bold></td></tr><tr><td align="left">Pre-menopause (&lt; 50 years)</td><td align="left">6</td></tr><tr><td align="left">Post-menopause (&gt; 50 years)</td><td align="left">4</td></tr><tr><td align="left" colspan="2"><bold>Subtypes (N)</bold></td></tr><tr><td align="left">ER+/PR+/HER2+</td><td align="left">2</td></tr><tr><td align="left">ER+/PR+/HER2−</td><td align="left">4</td></tr><tr><td align="left">ER−/PR−/HER2+</td><td align="left">1</td></tr><tr><td align="left">ER−/PR−/HER2−</td><td align="left">3</td></tr><tr><td align="left" colspan="2"><bold>Nodal status</bold></td></tr><tr><td align="left">Number of positive nodes (N)</td><td align="left">15</td></tr><tr><td align="left">Patients with positive involvement (%)</td><td align="left">80%</td></tr><tr><td align="left">Patients without positive involvement (%)</td><td align="left">20%</td></tr></tbody></table><table-wrap-foot><p><italic>ER</italic> estrogen receptor, <italic>PR</italic> progesterone receptor, <italic>HER2</italic> human epidermal growth factor-2, <italic>MRI</italic> magnetic resonance imaging.</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec4">
                <title>
                  <italic>Comparison of [</italic>
                  <sup>
                    <italic>18</italic>
                  </sup>
                  <italic>F]FDG-dbPET and [</italic>
                  <sup>
                    <italic>18</italic>
                  </sup>
                  <italic>F]FDG-wbPET</italic>
                </title>
                <p id="Par6">Representative [<sup>18</sup>F]FDG-wbPET and -dbPET images of a 39-year-old breast cancer patient with an agglomerate of ER+/PR+/HER2+ tumors are shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. The primary tumor was highlighted in the left breast, with comparable maximum standardized uptake value normalized to lean body mass (SUL<sub>max</sub>) for both methods (wbPET 13.25 mL<sup>−1</sup> vs dbPET 10.57 mL<sup>−1</sup>). The primary difference observed between the dbPET and wbPET was the heterogeneity of the tumor in the ipsilateral breast. Due to the lower post-reconstruction voxel resolution (4 <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M2"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq1.gif"/></alternatives></inline-formula> 4 <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M4"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq2.gif"/></alternatives></inline-formula> 4 mm) and the smaller breast tumor tissue size relative to the total field of view (FOV), the primary tumor in the wbPET comprises a relatively small fraction of the total voxel volume (Fig. <xref rid="Fig1" ref-type="fig">1</xref>a, a inset). By contrast, dbPET had a higher in-tumor resolution (1 <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M6"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq3.gif"/></alternatives></inline-formula> 1 <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M8"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq4.gif"/></alternatives></inline-formula> 1 mm post-reconstruction) and highlighted the spatial heterogeneity (Fig. <xref rid="Fig1" ref-type="fig">1</xref>b). Signal intensity histograms of the tumor volume of interest (VOI) with fixed bin number (50 bins) were generated for wbPET (Fig. <xref rid="Fig1" ref-type="fig">1</xref>c) and dbPET (Fig. <xref rid="Fig1" ref-type="fig">1</xref>d). The observed qualitative differences in spatial and signal intensity heterogeneity in dbPET may be largely driven by the higher voxel resolution and tumor tissue fraction.<fig id="Fig1"><label>Figure 1</label><caption><p>An example of a 39-year-old breast cancer patient with an agglomerate of ER+/PR+/HER2+ tumors imaged by [<sup>18</sup>F]FDG-wbPET and -dbPET at the pre-treatment timepoint. (<bold>a</bold>) A maximum intensity projection of [<sup>18</sup>F]FDG-wbPET with primary lesions in the left ipsilateral breast (inset). (<bold>b</bold>) A maximum intensity projection of [<sup>18</sup>F]FDG-dbPET with corresponding highlighted tumors in the left ipsilateral breast (white arrows). (<bold>c</bold>) Histogram of SULs in the tumor VOI for wbPET. (<bold>d</bold>) Histogram of SULs in the tumor VOI for dbPET. Number of bins in (<bold>c</bold>,<bold>d</bold>) were restricted to 50.</p></caption><graphic xlink:href="41598_2020_78865_Fig1_HTML" id="MO1"/></fig></p>
                <p id="Par7">Uptake and metabolically active tumor volume statistics were calculated and compared for both modalities (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). SUL<sub>max</sub> (median difference (95% CI): 5.88 mL<sup>−1</sup> (2.88, 8.87 mL<sup>−1</sup>), <italic>p</italic> = 0.006), SUL<sub>mean</sub> (1.76 mL<sup>−1</sup> (0.89, 2.58 mL<sup>−1</sup>), <italic>p</italic> = 0.002), and SUL<sub>peak</sub> (4.01 mL<sup>−1</sup> (1.80, 6.40 mL<sup>−1</sup>), <italic>p</italic> = 0.006) were all statistical significantly higher for dbPET relative to wbPET (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a–c). The tumor-background ratios with contralateral breast normalization were similar [− 2.28 (− 9.14, 1.56), <italic>p</italic> = 0.16] for both modalities, although normalization of the wbPET tumor uptake by the liver VOI resulted in a statistically significant higher tumor-background ratio in dbPET relative to wbPET [7.87 (2.17, 13.71), <italic>p</italic> = 0.004]. The metabolic tumor volume (MTV) was reduced in dbPET [− 4.62 mL (− 23.91, 1.72 mL), <italic>p</italic> = 0.43], while the total lesion glycolysis (TLG) was higher in dbPET [17.63 (− 8.41, 49.15), <italic>p</italic> = 0.27] (Fig. <xref rid="Fig2" ref-type="fig">2</xref>e,f). The broad distribution of uptake and tumor volume statistics may be driven by inter-patient heterogeneity.<fig id="Fig2"><label>Figure 2</label><caption><p>Comparison of [<sup>18</sup>F]FDG uptake in lesions with dbPET and wbPET. (<bold>a</bold>) SUL<sub>max</sub>; (<bold>b</bold>) SUL<sub>mean</sub>; (<bold>c</bold>) SUL<sub>peak</sub>; (<bold>d</bold>) Ratio of SUL<sub>peak</sub> in tumor to SUL<sub>mean</sub> in the background. For wbPET, the background VOIs were defined separately on the liver and the contralateral breast. Background VOI was defined in the contralateral breast for dbPET. (<bold>e</bold>) Metabolic tumor volume (MTV); and (<bold>f</bold>) Total lesion glycolysis (TLG).</p></caption><graphic xlink:href="41598_2020_78865_Fig2_HTML" id="MO2"/></fig></p>
                <p id="Par8">Since the partial volume effect is driven by the lesion size and spatial resolution of reconstructed images, the cohort was also examined based on the MRI longest diameter (<italic>d</italic><sub>MRI</sub>) with a cutoff of 2.5 cm [median (IQR) 2.23 (2.2–2.33) cm, N = 4; 5.45 (3.9–6.48) cm, N = 6] (Table <xref rid="Tab2" ref-type="table">2</xref>). There was a 2.71-fold and 1.58-fold increase in SUL<sub>peak</sub> in dbPET compared to wbPET in the <italic>d</italic><sub>MRI</sub> ≤ 2.5 cm and <italic>d</italic><sub>MRI</sub> &gt; 2.5 cm groups, respectively. The smaller difference in uptake for the lesions with <italic>d</italic><sub>MRI</sub> &gt; 2.5 cm was expected as the impact on partial volume effect due to the spatial resolution difference between dbPET and wbPET is smaller for larger lesions<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. The differences between dbPET and wbPET in the uptake (SUL) and volume-derived measurements (MTV, TLG) generally increased in the smaller lesions (<italic>d</italic><sub>MRI</sub> ≤ 2.5 cm) than larger tumors (<italic>d</italic><sub>MRI</sub> &gt; 2.5 cm).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of dbPET and wbPET uptake metrics for MRI longest diameter (<italic>d</italic><sub>MRI</sub>) ≤ 2.5 cm and <italic>d</italic><sub>MRI</sub> &gt; 2.5 cm.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">dbPET [Median (IQR)]</th><th align="left" colspan="2">wbPET [Median (IQR)]</th></tr><tr><th align="left"><italic>d</italic><sub>MRI</sub> ≤ 2.5 cm</th><th align="left"><italic>d</italic><sub>MRI</sub> &gt; 2.5 cm</th><th align="left"><italic>d</italic><sub>MRI</sub> ≤ 2.5 cm</th><th align="left"><italic>d</italic><sub>MRI</sub> &gt; 2.5 cm</th></tr></thead><tbody><tr><td align="left">SUL<sub>max</sub></td><td align="left">12.39 (10.23–14.6)</td><td align="left">14.22 (9.46–17.92)</td><td align="left">7.52 (5.17–8.78)</td><td align="left">8.04 (5.23–11.38)</td></tr><tr><td align="left">SUL<sub>mean</sub></td><td align="left">5.78 (4.37–7.01)</td><td align="left">4.00 (3.45–5.32)</td><td align="left">3.56 (2.65–4.08)</td><td align="left">3.35 (2.87–4.18)</td></tr><tr><td align="left">SUL<sub>peak</sub></td><td align="left">11.05 (8.15–12.22)</td><td align="left">7.11 (5.38–10.05)</td><td align="left">4.07 (3.07–4.29)</td><td align="left">4.50 (3.51–6.81)</td></tr><tr><td align="left">Tumor-Background (Liver)</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">2.39 (1.87–2.64)</td><td align="left">2.71 (2.07–3.92)</td></tr><tr><td align="left">Tumor-Background (Contralateral breast)</td><td align="left">4.01 (3.65–7.17)</td><td align="left">13.41 (8.97–18.78)</td><td align="left">16.64 (7.09–24.44)</td><td align="left">14.22 (5.20–20.45)</td></tr><tr><td align="left">MTV</td><td align="left">9.00 (5.39–12.02)</td><td align="left">17.25 (10.39–44.53)</td><td align="left">5.8 (4.26–7.26)</td><td align="left">24.85 (16.49–79.56)</td></tr><tr><td align="left">TLG</td><td align="left">54.84 (24.51–84.43)</td><td align="left">83.57 (47.66–145.2)</td><td align="left">25.06 (16.19–30.34)</td><td align="left">64.53 (62.24–95.4)</td></tr></tbody></table></table-wrap></p>
                <p id="Par9">Finally, 20 tumor morphology, tumor signal intensity, and textural features were generated from both modalities (Table <xref rid="Tab3" ref-type="table">3</xref>). Spatial heterogeneity features, specifically the gray-level co-occurrence matrix (GLCM) correlation [median difference (95% CI) − 0.42 (− 0.60, − 0.25), <italic>p</italic> = 0.002], normalized inverse difference [− 0.05 (− 0.08, − 0.02), <italic>p</italic> = 0.002], and joint entropy [− 0.71 (− 2.30, − 0.15), <italic>p</italic> = 0.01], showed statistically significant difference between dbPET and wbPET. There was also a statistically significant decrease in mesh volume [− 11.00 mL (− 22.59, − 2.13 mL), <italic>p</italic> = 0.006] in dbPET relative to wbPET.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of radiomics features for dbPET and wbPET.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Features</th><th align="left">dbPET<break/>Median (IQR)</th><th align="left">wbPET<break/>Median (IQR)</th><th align="left">Median difference (95% CI)</th><th align="left">P-Value</th></tr></thead><tbody><tr><td align="left" rowspan="4">Morphology</td><td align="left">Mesh volume (cm<sup>3</sup>)</td><td align="left">6.08 (2.94–13.65)</td><td align="left">19.19 (7.36–26.87)</td><td align="left">− 11.00 (− 22.59, − 2.13)</td><td align="left"><bold>0.006</bold></td></tr><tr><td align="left">Surface area (cm<sup>2</sup>)</td><td align="left">26.12 (15.46–68.29)</td><td align="left">51.59 (25.28–92.57)</td><td align="left">− 17.76 (− 150.57, 2.66)</td><td align="left">0.77</td></tr><tr><td align="left">Sphericity</td><td align="left">0.65 (0.54–0.69)</td><td align="left">0.70 (0.58–0.74)</td><td align="left">− 0.03 (− 3.06, 0.90)</td><td align="left">0.43</td></tr><tr><td align="left">Maximum 3D Diameter (cm)</td><td align="left">4.24 (2.63–4.80)</td><td align="left">43.72 (34.37–72.71)</td><td align="left">− 1.13 (− 43.07, 0.22)</td><td align="left">0.28</td></tr><tr><td align="left" rowspan="5">Tumor Intensity</td><td align="left">Entropy</td><td align="left">7.96 (7.49–9.12)</td><td align="left">8.89 (8.02–10.33)</td><td align="left">− 1.12 (− 2.53, 0.3)</td><td align="left">0.28</td></tr><tr><td align="left">Uniformity</td><td align="left">5.1e−3 (2.1e−3–6.5e−3)</td><td align="left">2.4e−3 (9.5e−4–4.6e−3)</td><td align="left">6.3e−4 (− 0.003, 0.005)</td><td align="left">0.70</td></tr><tr><td align="left">Skewness</td><td align="left">0.90 (0.83–1.07)</td><td align="left">0.59 (0.43–0.76)</td><td align="left">0.32 (− 0.11, 0.65)</td><td align="left">0.13</td></tr><tr><td align="left">Kurtosis</td><td align="left">3.31 (2.74–3.62)</td><td align="left">2.69 (2.57–3.31)</td><td align="left">0.53 (− 0.63, 2.93)</td><td align="left">0.19</td></tr><tr><td align="left">Standard Deviation</td><td align="left">1.42 (0.99–2.09)</td><td align="left">1.7 (1.22–2.82)</td><td align="left">− 0.60 (− 3.06, 0.90)</td><td align="left">0.43</td></tr><tr><td align="left" rowspan="6">GLCM</td><td align="left">Contrast</td><td align="left">2.6e4 (1.4e4–7.7e4)</td><td align="left">1.9e4 (7.2e3–2e5)</td><td align="left">6.8e3 (− 3.6e5, 1.1e5)</td><td align="left">0.92</td></tr><tr><td align="left">Correlation</td><td align="left">0.43 (0.27–0.54)</td><td align="left">0.78 (0.76–0.84)</td><td align="left">− 0.42 (− 0.60, − 0.25)</td><td align="left"><bold>0.002</bold></td></tr><tr><td align="left">Inverse Difference</td><td align="left">0.03 (0.02–0.04)</td><td align="left">0.03 (0.01–0.05)</td><td align="left">− 0.01 (− 0.11, 0.01)</td><td align="left">0.56</td></tr><tr><td align="left">Normalized Inverse Difference</td><td align="left">0.87 (0.84–0.90)</td><td align="left">0.92 (0.90–0.93)</td><td align="left">− 0.05 (− 0.08, − 0.02)</td><td align="left"><bold>0.002</bold></td></tr><tr><td align="left">Joint Energy</td><td align="left">9.01e−4 (4.5e−4–0.002)</td><td align="left">6.5e−4 (2.4e−4–9.7e−4)</td><td align="left">5.14e−4 (− 1.86e−5, 8.37e−3)</td><td align="left">0.084</td></tr><tr><td align="left">Joint Entropy</td><td align="left">10.17 (8.93–11.13)</td><td align="left">10.97 (10.03–12.06)</td><td align="left">− 0.71 (− 2.30, − 0.15)</td><td align="left"><bold>0.01</bold></td></tr><tr><td align="left" rowspan="5">NGTDM</td><td align="left">Busyness</td><td align="left">0.008 (0.003–0.019)</td><td align="left">8.2e−4 (2.8e−4–1.4e−3)</td><td align="left">0.004 (− 0.04, 0.01)</td><td align="left">0.0840</td></tr><tr><td align="left">Coarseness</td><td align="left">0.003 (0.002–0.007)</td><td align="left">0.006 (0.003–0.009)</td><td align="left">− 0.002 (− 0.005, 0.007)</td><td align="left">0.2324</td></tr><tr><td align="left">Complexity</td><td align="left">4.6e6 (2e6–3.7e7)</td><td align="left">8.7e6 (1.7e6–2.8e8)</td><td align="left">− 4.69e6 (− 1.97e9, 5.37e7)</td><td align="left">0.7695</td></tr><tr><td align="left">Contrast</td><td align="left">31.52 (10.06–116.78)</td><td align="left">10.8 (8.05–49.11)</td><td align="left">42.24 (− 26.82, 242.48)</td><td align="left">0.2754</td></tr><tr><td align="left">Strength</td><td align="left">490.9 (248.9–1.6e3)</td><td align="left">2.4e3 (1.4e3–6.6e3)</td><td align="left">− 0.001 (− 1.4e4, 176.6)</td><td align="left">0.1602</td></tr></tbody></table><table-wrap-foot><p>Statistical significance, median difference, and 95% confidence intervals were assessed using the Wilcoxon signed-rank test.</p><p><italic>GLCM</italic> gray-level co-occurrence matrix, <italic>NGTDM</italic> neighborhood gray-tone difference matrix.</p></table-wrap-foot></table-wrap></p>
              </sec>
            </sec>
            <sec id="Sec5">
              <title>Discussion</title>
              <p id="Par10">The motivation for this study was to compare the performance of primary tumor characterization between [<sup>18</sup>F]FDG-dbPET and [<sup>18</sup>F]FDG-wbPET in a pilot study of breast cancer patients. WbPET is primarily used for staging and can detect metastases and nodal involvement, which are necessary to devise treatment strategies. However, due to the collapsed breast volumes and low relative tumor tissue fraction, wbPET may be limited in precise and quantitative characterization of the primary tumor for studying therapeutic response. Here, we examine the similarities and differences in the distribution of [<sup>18</sup>F]FDG uptake in dbPET and wbPET at the pre-treatment time point.</p>
              <p id="Par11">Steady-state uptake metrics were used to characterize [<sup>18</sup>F]FDG-wbPET and -dbPET. As suggested by the PET Response Criteria in Solid Tumors (PERCIST), the lean body mass was used to generate SULs to account for the dual effects of body weight and height on uptake<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. In general, overall [<sup>18</sup>F]FDG uptake values (SUL<sub>max</sub>, SUL<sub>mean</sub>, and SUL<sub>peak</sub>) in the primary tumor were higher in dbPET compared to wbPET. SUL<sub>peak</sub> is considered more robust than SUL<sub>max</sub> and SUL<sub>mean</sub> due to its insensitivity to voxel-wise variations. The higher dbPET SUL<sub>peak</sub> reflects the sensitivity and dynamic range required for detecting changes in tumor uptake following treatment, although the relative increase in the dynamic range and sensitivity is likely paired with increased background noise. To minimize the effect of background noise, a threshold for dbPET with SUV ≥ 3.0 was applied to define tumor boundaries. The calculation of SUL<sub>peak</sub> involves mean filtering with a 1.2 cm spherical kernel, which may further reduce the effect of the increased background signal on the presented SUL<sub>peak</sub>. Although the results did not reach statistical significance, MTV and TLG were estimated to be higher in wbPET compared to dbPET. These trends suggest a role for the partial volume effect, due to lower spatial resolution and tumor tissue fraction in wbPET<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Post hoc analysis of SULs and tumor volume supports this analysis, with the observed increases in dbPET-measured SUL<sub>peak</sub>, MTV, and TLG in lesions with <italic>d</italic><sub>MRI</sub> ≤ 2.5 cm.</p>
              <p id="Par12">To account for variability introduced by the surrounding tissue, the tumor signal is often normalized by the background VOI. In [<sup>18</sup>F]FDG-wbPET, the background VOI is defined in the liver in the absence of liver metastases, due to its perfused and homogenous uptake of [<sup>18</sup>F]FDG. However, this normalization method was not available for dbPET and the contralateral breast was used. This method resulted in a fourfold increase of tumor-background ratio in dbPET compared to wbPET using liver as the background. While the contralateral tissue is a logical background tissue for dbPET, careful consideration should be taken if there is bilateral disease. We observed inter-patient heterogeneity in the contralateral breast background signal in both modalities, which resulted in minimal difference in tumor-background ratio following normalization by the contralateral breast in wbPET. Similar variation in background parenchymal FDG uptake have been observed in other studies<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. While limiting the PET scans at the early follicular phase of the menstrual cycle may minimize the background parenchymal signal<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, the patient’s treatment planning should be taken into consideration for scheduling without imposing additional burden. Finally, radiomic features pertaining to heterogeneity and tumor morphology were calculated within the tumor VOI for dbPET and wbPET. The improved spatial resolution within the primary breast tumor and increased tumor tissue fraction in dbPET relative to wbPET have been previously reported, and qualitatively represented in an increase of metabolic heterogeneity in the tumor in a cohort of 35 patients<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. While textural features of the primary tumor from dbPET images have been analyzed based on breast cancer subtypes<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>, the similarities and differences of these features have not been assessed between dbPET and wbPET. The chosen features have been identified in the literature to be most reflective of changes in spatial and intensity heterogeneity<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> and robust to imaging conditions and reconstruction parameters<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. To prevent resolution biases from affecting feature calculations, dbPET and wbPET images were down-sampled and up-sampled, respectively, to an isotropic voxel size (2 <inline-formula id="IEq5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M10"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq5.gif"/></alternatives></inline-formula> 2 <inline-formula id="IEq6"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M12"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq6.gif"/></alternatives></inline-formula> 2 mm). Morphological features were concordant with standard uptake volume metrics (MTV and TLG), especially mesh volume, which was found to be significantly different between the two modalities. Statistically significant difference was also observed in features corresponding to spatial heterogeneity, specifically GLCM normalized inverse difference, joint entropy, and correlation. The differences in textural heterogeneity features correlate to the observed, qualitative differences between dbPET and wbPET and may be primarily driven by the increased sensitivity in dbPET.</p>
              <p id="Par13">The [<sup>18</sup>F]FDG-dbPET results in this study are concordant with literature of positron emission mammography (PEM, NaviScan, CA) and previous cohorts with the MAMMI and Elmammo (Shimadzu, Japan) dbPET systems. In a cohort of 388 patients with primary breast lesions, PEM showed comparable accuracy to MRI with improved sensitivity compared to wbPET for quantifying primary lesions<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. Similar to dbPET, PEM had a smaller FOV focusing on the primary lesion at the expense of metastatic lesions, although breast compression and hardware design resulted in limited resolution with maximum intensity projection of 2D images<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. The sensitivity, spatial resolution, and dose for dbPET in our study recapitulated observations in a cohort of 234 breast cancer patients who received [<sup>18</sup>F]FDG-dbPET and wbPET/CT for staging<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. In that study, sub-centimeter lesions in the ipsilateral breast were identified by dbPET that were not resolved in the wbPET images. Similarly, using the Elmammo system, Sasada et al. compared bilateral [<sup>18</sup>F]FDG-dbPET to [<sup>18</sup>F]FDG-wbPET in a 47-patient cohort following NAC and observed that the tumor-background ratio was more sensitive than SUV<sub>max</sub> to treatment response<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Nishimatsu et al<italic>.</italic> also observed higher tumor-background ratios in dbPET relative to wbPET in a cohort of 150 patients, although there was no observable difference in sensitivity to lesion detection<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. In our study, the SUL<sub>peak</sub> was higher in dbPET, suggesting a larger dynamic range and potentially, higher sensitivity to treatment-induced changes in [<sup>18</sup>F]FDG uptake. Furthermore, analysis of radiomic features identified statistically significant differences in GLCM-derived textural heterogeneity markers between dbPET and wbPET.</p>
              <p id="Par14">The limitations of our study are largely driven by hardware design and cohort construction issues. Lesions adjacent to the chest wall experienced limited resolution and incidental scatter from the heart, resulting in inaccurate quantification of uptake. This issue may be mitigated in future studies by using an enlarged aperture on the scan bed, a thinner chest resting area, and a flexible silicone sleeve to gain more breast tissues near the chest wall to be scanned within the detector field of view. An improved reconstruction algorithm as described by O’Connor et al<italic>.</italic><sup><xref ref-type="bibr" rid="CR18">18</xref></sup> will be installed to reduce the presence of crosstalk in the breast from FDG signals in the myocardium.</p>
              <p id="Par15">In addition, this pilot study had a limited sample size that prohibited additional analyses based on breast cancer subtypes. While our objective was to compare the [<sup>18</sup>F]FDG signal distribution in dbPET and wbPET, results from this small cohort cannot be generalized. Study inclusion criteria placed a lower bound on tumor sizes at 2 cm, which limited the study of smaller lesions with high potential for partial volume effect. Since the wbPET was part of a routine clinical procedure, wbPET data included in this report were acquired using different systems with various reconstruction algorithms, depending on clinical availability. SUVs generated across vendors at multiple sites are known to possess coefficients of variation of up to 5%, although this error may be reduced through frequent calibrations<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. The different wbPET scanners and reconstruction algorithms may also affect radiomics feature stability. To prevent undue adverse effect on reproducibility for wbPET features, we selected more robust and repeatable GLCM features<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup> in this study. Additionally, tumor-masked images were rescaled to an isotropic resolution and quantized to discrete gray-levels with a fixed bin width<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> to prevent intensity-driven heterogeneity from affecting the radiomics results. Finally, the patient cohort was mostly locally advanced stage II/III patients from a single institution, which may not be representative of the general breast cancer patient population.</p>
              <p id="Par16">In this study, we assessed similarities and differences in [<sup>18</sup>F]FDG uptake between wbPET and dbPET. SUL<sub>peak</sub> and SUL<sub>max</sub> are well recognized as predictors of treatment response and showed consistently higher values measured by dbPET compared to wbPET. While dbPET is not designed to detect metastatic disease for staging, it serves as an adjunct to wbPET and breast MRI for breast tumor characterization<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Compared to wbPET, the higher dbPET readout also reflects the higher sensitivity and broader dynamic range for detecting treatment-induced changes in the primary non-metastatic tumor, providing powerful molecular insights to guide treatment selection and to better assess early molecular changes in response to treatment.</p>
              <p id="Par17">The increased spatial resolution and reduced [<sup>18</sup>F]FDG dose used in dbPET makes it an attractive modality for treatment monitoring and supports further analyses using higher-order radiomic features to quantify changes in tumor burden and intratumoral heterogeneity for treatment stratification and prediction of survival outcomes. Future studies with this technology would utilize larger cohorts and receptor-specific radiotracers to improve stratification.</p>
            </sec>
            <sec id="Sec6">
              <title>Methods</title>
              <sec id="Sec7">
                <title>Ethics statement</title>
                <p id="Par18">Ten patients with biopsy-confirmed breast cancer were recruited to participate in an imaging study with [<sup>18</sup>F]FDG-dbPET (MAMMI, General Equipment and Medical Imaging SA (OncoVision), Valencia, Spain). This study was in compliance with the HIPAA-compliant study protocol that was reviewed by the UCSF Institutional Review Board and approved by the Committee of Human Research under the institution Human Research Program. All procedures performed were in compliance with relevant guidelines and regulations. All patients were required to provide written informed consent to participate.</p>
              </sec>
              <sec id="Sec8">
                <title>Study population</title>
                <p id="Par19">Patient eligibility was established on the basis of histopathological evaluation of biopsy samples. Breast MRI was performed as a standard of care to measure the extent of the tumor burden and size, while [<sup>18</sup>F]FDG-wbPET was used for staging.</p>
              </sec>
              <sec id="Sec9">
                <title>
                  <italic>[</italic>
                  <sup>
                    <italic>18</italic>
                  </sup>
                  <italic>F]FDG-dbPET acquisition</italic>
                </title>
                <p id="Par20">DbPET was performed with [<sup>18</sup>F]FDG (range 121.0–199.8 MBq, median 185.7 MBq). Patients fasted 6 h prior to imaging and blood glucose was measured before intravenous [<sup>18</sup>F]FDG administration. Following 45 min of incubation, the subjects were scanned in a prone position, with a single breast positioned through the aperture into the detector ring. The detector ring translated axially from inferior to superior for approximately 15 min, with the frame duration determined by the total length of the breast. DbPET images were reconstructed in 3D using manufacturer-provided maximum-likelihood expectation maximization with a 1 mm kernel and 16 iterations. The post-reconstruction resolution was standardized to 1 <inline-formula id="IEq7"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M14"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq7.gif"/></alternatives></inline-formula> 1 <inline-formula id="IEq8"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M16"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq8.gif"/></alternatives></inline-formula> 1 mm. Both breasts were scanned consecutively in the same imaging session.</p>
              </sec>
              <sec id="Sec10">
                <title>
                  <italic>[</italic>
                  <sup>
                    <italic>18</italic>
                  </sup>
                  <italic>F]FDG-wbPET acquisition</italic>
                </title>
                <p id="Par21">WbPET with computed tomography (wbPET/CT) was performed as part of disease staging and routine clinical procedure. As with dbPET, patients fasted for approximately 6 h prior to the scan, and blood glucose levels were measured before intravenous [<sup>18</sup>F]FDG administration (range 229.4–392.6 MBq, median 301.6 MBq). After approximately 50–60 min of incubation, patients were scanned in the supine position through the PET/CT gantry, translating anterior to posterior for approximately 30 min. Depending on the clinical availability, wbPET data included in this report were acquired using three PET/CT scanners: GE Discovery VCT PET/CT (GE Healthcare, WI), Philips Gemini TF PET/CT, and Philips Vereos PET/CT (Philips Healthcare, MA). All wbPET images were acquired in 3D and reconstructed using manufacturer-provided iterative reconstruction algorithms that included CT-based attenuation and scatter corrections. The standard whole-body image reconstruction algorithms were: 3D ordered subsets expectation maximization (OS-EM) with 28 subsets and 2 iterations for GE Discovery VCT PET/CT; Blob-based iterative time-of-flight reconstruction algorithm (BLOB-OS-TF) with 3 iterations and 33 subsets for Philips Gemini TF PET/CT; Time-of-flight OS-EM with 3 iterations and 15 subsets for Philips Vereos PET/CT. The most common post-reconstruction voxel resolution across systems was 4 <inline-formula id="IEq9"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M18"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq9.gif"/></alternatives></inline-formula> 4 <inline-formula id="IEq10"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M20"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq10.gif"/></alternatives></inline-formula> 4 mm (other voxel resolutions in the study: 5.5 <inline-formula id="IEq11"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M22"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq11.gif"/></alternatives></inline-formula> 5.5 <inline-formula id="IEq12"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M24"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq12.gif"/></alternatives></inline-formula> 3.3 mm, 3.6 <inline-formula id="IEq13"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M26"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq13.gif"/></alternatives></inline-formula> 3.6 <inline-formula id="IEq14"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M28"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq14.gif"/></alternatives></inline-formula> 3.3 mm).</p>
              </sec>
              <sec id="Sec11">
                <title>PET data analysis</title>
                <p id="Par22">To compare wbPET and dbPET [<sup>18</sup>F]FDG uptake, reconstructed images were first converted to decay-corrected standardized uptake values normalized by body weight (SUV) and lean body mass (SUL). Semi-automated segmentation of the tumor volume of interest (VOI) was performed over the entire volume of the high uptake lesion (OsiriX, Pixmeo, Switzerland) with a threshold of SUV ≥ 2.5 and 3.0 for wbPET and dbPET, respectively. Background SUVs were measured by placing a 1.2 cm cylindrical mask at the centroid of the contralateral breast for dbPET and a 1.2 cm spherical mask in the liver and contralateral breast for wbPET. Following segmentation, the single voxel maximum, average, and peak uptake (SUL<sub>max</sub>, SUL<sub>mean</sub>, SUL<sub>peak</sub>) were computed as per the standard PET Response Criteria in Solid Tumors (PERCIST), while the metabolic tumor volume (MTV) was calculated as the summing of voxel volumes with SUV ≥ 40% SUV<sub>mean</sub><sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. The total lesion glycolysis (TLG) was computed as the product of the MTV and SUV<sub>mean</sub>.</p>
                <p id="Par23">Radiomic features were computed within the tumor VOIs using Python 3.7. Images were first re-segmented in 3D Slicer 4.11<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> and resampled to an isotropic resolution (2 <inline-formula id="IEq15"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M30"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq15.gif"/></alternatives></inline-formula> 2 <inline-formula id="IEq16"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><mml:math id="M32"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="41598_2020_78865_Article_IEq16.gif"/></alternatives></inline-formula> 2 mm<sup>3</sup>) using linear interpolation and quantized to discrete gray-levels using a fixed bin width<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup>. Radiomics calculation was performed on these discretized images.</p>
                <p id="Par24">A total of 20 features describing tumor morphology and heterogeneity were calculated using the PyRadiomics package according to the Image Biomarker Standardization Initiative recommendations<sup><xref ref-type="bibr" rid="CR42">42</xref>–<xref ref-type="bibr" rid="CR44">44</xref></sup>. In particular, heterogeneity features were evaluated from intensity distribution and texture analysis, specifically the grey-level co-occurrence matrix (GLCM) and neighborhood grey-tone difference matrix (NGTDM)<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. Prior to the calculation of textural features, SUV images were harmonized in accordance to literature methods<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. The data were rescaled to discretized grey levels with a bin width of 0.5. GLCM and NGTDM features were calculated on the 3D volume masked by the tumor VOI with nearest neighbor distances (<italic>d</italic> = 1) and averaging of each angle-specific matrix. The GLCM and NGTDM classes describe neighboring pixel and regional textures, respectively.</p>
                <p id="Par25">All statistical analyses were performed using R v. 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria). Statistical significance, median difference, and 95% confidence intervals (CI) were assessed using the non-parametric Wilcoxon signed-rank test. <italic>p</italic>-values less than 0.05 were considered significant.</p>
              </sec>
              <sec id="Sec12">
                <title>Consent to participate</title>
                <p id="Par26">All patients provided written informed consent to participate.</p>
              </sec>
              <sec id="Sec13">
                <title>Consent for publication</title>
                <p id="Par27">All patients provided written informed consent for publication.</p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher's note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>This work was supported in part by the Department of Defense BC171237, National Institute of Health R01CA227763, UCSF Breast Oncology Program, the Mount Zion Health Fund (20160729 [CA-0097143]), and the Give Breast Cancer the Boot Fund (7028391). The authors would also like to acknowledge Margarita Watkins and Ruby Guo for their assistance with patient accrual and coordination, as well as Chloee Wendorf and Michael White for their assistance with resource allocation for [<sup>18</sup>F]FDG injection.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>E.F.J. conceived and planned the experiments. E.F.J., D.K.H., and W.L. carried out the experiments. B.N.J. reviewed the breast MR images. R.R.F. and B.L.F. reviewed the dbPET and wbPET images. L.J.E. reviewed cases and referred breast cancer patients. Y.S. contributed to the dbPET signal quantification and N.M.H. contributed to the MRI signal quantification. J.K. reviewed the statistical analyses. D.K.H. and E.F.J. took the lead in writing the manuscript. All authors provided critical feedback and helped shape the research, analysis and manuscript.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>Data will be available upon request.</p>
            </notes>
            <notes id="FPar1" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par28">The authors declare no competing interests.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Polyak</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Heterogeneity in breast cancer</article-title>
                  <source>J. Clin. Investig.</source>
                  <year>2011</year>
                  <volume>121</volume>
                  <fpage>3786</fpage>
                  <lpage>3788</lpage>
                  <pub-id pub-id-type="doi">10.1172/JCI60534</pub-id>
                  <?supplied-pmid 21965334?>
                  <pub-id pub-id-type="pmid">21965334</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rouzier</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Breast cancer molecular subtypes respond differently to preoperative chemotherapy</article-title>
                  <source>Clin. Cancer Res.</source>
                  <year>2005</year>
                  <volume>11</volume>
                  <fpage>5678</fpage>
                  <lpage>5685</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2421</pub-id>
                  <?supplied-pmid 16115903?>
                  <pub-id pub-id-type="pmid">16115903</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van’t Veer</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title>
                  <source>Nature</source>
                  <year>2002</year>
                  <volume>415</volume>
                  <fpage>530</fpage>
                  <lpage>536</lpage>
                  <pub-id pub-id-type="doi">10.1038/415530a</pub-id>
                  <pub-id pub-id-type="pmid">11823860</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fallahpour</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Navaneelan</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>De</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Borgo</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Breast cancer survival by molecular subtype: A population-based analysis of cancer registry data</article-title>
                  <source>CMAJ Open</source>
                  <year>2017</year>
                  <volume>5</volume>
                  <fpage>E734</fpage>
                  <lpage>e739</lpage>
                  <pub-id pub-id-type="doi">10.9778/cmajo.20170030</pub-id>
                  <?supplied-pmid 28951445?>
                  <pub-id pub-id-type="pmid">28951445</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Perou</surname>
                      <given-names>CM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Molecular portraits of human breast tumours</article-title>
                  <source>Nature</source>
                  <year>2000</year>
                  <volume>406</volume>
                  <fpage>747</fpage>
                  <lpage>752</lpage>
                  <pub-id pub-id-type="doi">10.1038/35021093</pub-id>
                  <?supplied-pmid 10963602?>
                  <pub-id pub-id-type="pmid">10963602</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rivenbark</surname>
                      <given-names>AG</given-names>
                    </name>
                    <name>
                      <surname>O'Connor</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Coleman</surname>
                      <given-names>WB</given-names>
                    </name>
                  </person-group>
                  <article-title>Molecular and cellular heterogeneity in breast cancer: Challenges for personalized medicine</article-title>
                  <source>Am. J. Pathol.</source>
                  <year>2013</year>
                  <volume>183</volume>
                  <fpage>1113</fpage>
                  <lpage>1124</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ajpath.2013.08.002</pub-id>
                  <?supplied-pmid 23993780?>
                  <pub-id pub-id-type="pmid">23993780</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Barker</surname>
                      <given-names>AD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy</article-title>
                  <source>Clin. Pharmacol. Ther.</source>
                  <year>2009</year>
                  <volume>86</volume>
                  <fpage>97</fpage>
                  <lpage>100</lpage>
                  <pub-id pub-id-type="doi">10.1038/clpt.2009.68</pub-id>
                  <?supplied-pmid 19440188?>
                  <pub-id pub-id-type="pmid">19440188</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kong</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Moran</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Haffty</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>Q</given-names>
                    </name>
                  </person-group>
                  <article-title>Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients</article-title>
                  <source>Eur. J. Cancer</source>
                  <year>2011</year>
                  <volume>47</volume>
                  <fpage>2084</fpage>
                  <lpage>2090</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejca.2011.06.014</pub-id>
                  <?supplied-pmid 21737257?>
                  <pub-id pub-id-type="pmid">21737257</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mghanga</surname>
                      <given-names>FP</given-names>
                    </name>
                    <name>
                      <surname>Lan</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Bakari</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: A meta-analysis</article-title>
                  <source>Clin. Breast Cancer</source>
                  <year>2013</year>
                  <volume>13</volume>
                  <fpage>271</fpage>
                  <lpage>279</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.clbc.2013.02.003</pub-id>
                  <?supplied-pmid 23714689?>
                  <pub-id pub-id-type="pmid">23714689</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Connolly</surname>
                      <given-names>RM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>TBCRC 008: Early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer</article-title>
                  <source>J. Nucl. Med.</source>
                  <year>2015</year>
                  <volume>56</volume>
                  <fpage>31</fpage>
                  <lpage>37</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.114.144741</pub-id>
                  <?supplied-pmid 25476537?>
                  <pub-id pub-id-type="pmid">25476537</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Groheux</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Mankoff</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Espie</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hindie</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: Review of the literature and recommendations for use in clinical trials</article-title>
                  <source>Eur. J. Nucl. Med. Mol. Imaging</source>
                  <year>2016</year>
                  <volume>43</volume>
                  <fpage>983</fpage>
                  <lpage>993</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00259-015-3295-z</pub-id>
                  <?supplied-pmid 26758726?>
                  <pub-id pub-id-type="pmid">26758726</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van Ramshorst</surname>
                      <given-names>MS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Additional value of (18)F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer</article-title>
                  <source>Cancer Imaging</source>
                  <year>2017</year>
                  <volume>17</volume>
                  <fpage>15</fpage>
                  <pub-id pub-id-type="doi">10.1186/s40644-017-0117-5</pub-id>
                  <?supplied-pmid 28545563?>
                  <pub-id pub-id-type="pmid">28545563</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Groheux</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Espie</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Giacchetti</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Hindie</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Performance of FDG PET/CT in the clinical management of breast cancer</article-title>
                  <source>Radiology</source>
                  <year>2013</year>
                  <volume>266</volume>
                  <fpage>388</fpage>
                  <lpage>405</lpage>
                  <pub-id pub-id-type="doi">10.1148/radiol.12110853</pub-id>
                  <?supplied-pmid 23220901?>
                  <pub-id pub-id-type="pmid">23220901</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Soret</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bacharach</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Buvat</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Partial-volume effect in PET tumor imaging</article-title>
                  <source>J. Nucl. Med.</source>
                  <year>2007</year>
                  <volume>48</volume>
                  <fpage>932</fpage>
                  <lpage>945</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.106.035774</pub-id>
                  <?supplied-pmid 17504879?>
                  <pub-id pub-id-type="pmid">17504879</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Teixeira</surname>
                      <given-names>SC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Additional prone 18F-FDG PET/CT acquisition to improve the visualization of the primary tumor and regional lymph node metastases in stage II/III breast cancer</article-title>
                  <source>Clin. Nucl. Med.</source>
                  <year>2016</year>
                  <volume>41</volume>
                  <fpage>e181</fpage>
                  <lpage>186</lpage>
                  <pub-id pub-id-type="doi">10.1097/RLU.0000000000001101</pub-id>
                  <?supplied-pmid 26704731?>
                  <pub-id pub-id-type="pmid">26704731</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Koolen</surname>
                      <given-names>BB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Molecular imaging in breast cancer: From whole-body PET/CT to dedicated breast PET</article-title>
                  <source>J. Oncol.</source>
                  <year>2012</year>
                  <volume>2012</volume>
                  <fpage>438647</fpage>
                  <pub-id pub-id-type="doi">10.1155/2012/438647</pub-id>
                  <?supplied-pmid 22848217?>
                  <pub-id pub-id-type="pmid">22848217</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Teixeira</surname>
                      <given-names>SC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Evaluation of a hanging-breast PET system for primary tumor visualization in patients with stage I–III breast cancer: Comparison with standard PET/CT</article-title>
                  <source>AJR Am. J. Roentgenol.</source>
                  <year>2016</year>
                  <volume>206</volume>
                  <fpage>1307</fpage>
                  <lpage>1314</lpage>
                  <pub-id pub-id-type="doi">10.2214/ajr.15.15371</pub-id>
                  <?supplied-pmid 27058014?>
                  <pub-id pub-id-type="pmid">27058014</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>O'Connor</surname>
                      <given-names>MK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Improved visualization of breast tissue on a dedicated breast PET system through ergonomic redesign of the imaging table</article-title>
                  <source>EJNMMI Res.</source>
                  <year>2017</year>
                  <volume>7</volume>
                  <fpage>100</fpage>
                  <pub-id pub-id-type="doi">10.1186/s13550-017-0351-7</pub-id>
                  <?supplied-pmid 29260333?>
                  <pub-id pub-id-type="pmid">29260333</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moliner</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Design and evaluation of the MAMMI dedicated breast PET</article-title>
                  <source>Med. Phys.</source>
                  <year>2012</year>
                  <volume>39</volume>
                  <fpage>5393</fpage>
                  <lpage>5404</lpage>
                  <pub-id pub-id-type="doi">10.1118/1.4742850</pub-id>
                  <pub-id pub-id-type="pmid">22957607</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jones</surname>
                      <given-names>EF</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Dedicated breast positron emission tomography for the evaluation of early response to neoadjuvant chemotherapy in breast cancer</article-title>
                  <source>Clin. Breast Cancer</source>
                  <year>2017</year>
                  <volume>17</volume>
                  <fpage>e155</fpage>
                  <lpage>e159</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.clbc.2016.12.008</pub-id>
                  <?supplied-pmid 28110902?>
                  <pub-id pub-id-type="pmid">28110902</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jones</surname>
                      <given-names>EF</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol</article-title>
                  <source>NPJ Breast Cancer</source>
                  <year>2019</year>
                  <volume>5</volume>
                  <fpage>12</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41523-019-0107-9</pub-id>
                  <?supplied-pmid 31016232?>
                  <pub-id pub-id-type="pmid">31016232</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Teo</surname>
                      <given-names>BK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Partial-volume correction in PET: Validation of an iterative postreconstruction method with phantom and patient data</article-title>
                  <source>J. Nucl. Med.</source>
                  <year>2007</year>
                  <volume>48</volume>
                  <fpage>802</fpage>
                  <lpage>810</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.106.035576</pub-id>
                  <?supplied-pmid 17475970?>
                  <pub-id pub-id-type="pmid">17475970</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Joo Hyun</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Lodge</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Wahl</surname>
                      <given-names>RL</given-names>
                    </name>
                  </person-group>
                  <article-title>Practical PERCIST: A simplified guide to PET response criteria in solid tumors 10</article-title>
                  <source>Radiology</source>
                  <year>2016</year>
                  <volume>280</volume>
                  <fpage>576</fpage>
                  <lpage>584</lpage>
                  <pub-id pub-id-type="doi">10.1148/radiol.2016142043</pub-id>
                  <pub-id pub-id-type="pmid">26909647</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Leithner</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Multiparametric 18F-FDG PET/MRI of the breast: Are there differences in imaging biomarkers of contralateral healthy tissue between patients with and without breast cancer?</article-title>
                  <source>J. Nucl. Med.</source>
                  <year>2020</year>
                  <volume>61</volume>
                  <fpage>20</fpage>
                  <lpage>25</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.119.230003</pub-id>
                  <?supplied-pmid 31253745?>
                  <pub-id pub-id-type="pmid">31253745</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kim</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer</article-title>
                  <source>Eur. J. Radiol.</source>
                  <year>2019</year>
                  <volume>110</volume>
                  <fpage>163</fpage>
                  <lpage>168</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejrad.2018.11.031</pub-id>
                  <?supplied-pmid 30599855?>
                  <pub-id pub-id-type="pmid">30599855</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Aliu</surname>
                      <given-names>SO</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Repeatability of quantitative MRI measurements in normal breast tissue</article-title>
                  <source>Transl. Oncol.</source>
                  <year>2014</year>
                  <volume>7</volume>
                  <fpage>130</fpage>
                  <lpage>137</lpage>
                  <pub-id pub-id-type="doi">10.1593/tlo.13841</pub-id>
                  <?supplied-pmid 24772216?>
                  <pub-id pub-id-type="pmid">24772216</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pengel</surname>
                      <given-names>KE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Combined use of (1)(8)F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy</article-title>
                  <source>Eur. J. Nucl. Med. Mol. Imaging</source>
                  <year>2014</year>
                  <volume>41</volume>
                  <fpage>1515</fpage>
                  <lpage>1524</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00259-014-2770-2</pub-id>
                  <?supplied-pmid 24777490?>
                  <pub-id pub-id-type="pmid">24777490</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moscoso</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Texture analysis of high-resolution dedicated breast (18) F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer</article-title>
                  <source>Eur. J. Nucl. Med. Mol. Imaging</source>
                  <year>2018</year>
                  <volume>45</volume>
                  <fpage>196</fpage>
                  <lpage>206</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00259-017-3830-1</pub-id>
                  <?supplied-pmid 28936601?>
                  <pub-id pub-id-type="pmid">28936601</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hall-Beyer</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Practical guidelines for choosing GLCM textures to use in landscape classification tasks over a range of moderate spatial scales</article-title>
                  <source>Int. J. Remote Sens.</source>
                  <year>2017</year>
                  <volume>38</volume>
                  <fpage>1312</fpage>
                  <lpage>1338</lpage>
                  <pub-id pub-id-type="doi">10.1080/01431161.2016.1278314</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Park</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Heo</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>KJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Reliability of CT radiomic features reflecting tumour heterogeneity according to image quality and image processing parameters</article-title>
                  <source>Sci. Rep.</source>
                  <year>2020</year>
                  <volume>10</volume>
                  <fpage>3852</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41598-020-60868-9</pub-id>
                  <?supplied-pmid 32123281?>
                  <pub-id pub-id-type="pmid">32123281</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Berg</surname>
                      <given-names>WA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Breast cancer: Comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast</article-title>
                  <source>Radiology</source>
                  <year>2011</year>
                  <volume>258</volume>
                  <fpage>59</fpage>
                  <lpage>72</lpage>
                  <pub-id pub-id-type="doi">10.1148/radiol.10100454</pub-id>
                  <?supplied-pmid 21076089?>
                  <pub-id pub-id-type="pmid">21076089</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Thompson</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Murthy</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Weinberg</surname>
                      <given-names>IN</given-names>
                    </name>
                    <name>
                      <surname>Mako</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Feasibility study for positron emission mammography</article-title>
                  <source>Med. Phys.</source>
                  <year>1994</year>
                  <volume>21</volume>
                  <fpage>529</fpage>
                  <lpage>538</lpage>
                  <pub-id pub-id-type="doi">10.1118/1.597169</pub-id>
                  <?supplied-pmid 8058019?>
                  <pub-id pub-id-type="pmid">8058019</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sasada</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study</article-title>
                  <source>Eur. J. Surg. Oncol.</source>
                  <year>2018</year>
                  <volume>44</volume>
                  <fpage>444</fpage>
                  <lpage>448</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejso.2018.01.014</pub-id>
                  <?supplied-pmid 29396328?>
                  <pub-id pub-id-type="pmid">29396328</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nishimatsu</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Higher breast cancer conspicuity on dbPET compared to WB-PET/CT</article-title>
                  <source>Eur. J. Radiol.</source>
                  <year>2017</year>
                  <volume>90</volume>
                  <fpage>138</fpage>
                  <lpage>145</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejrad.2017.02.046</pub-id>
                  <?supplied-pmid 28583624?>
                  <pub-id pub-id-type="pmid">28583624</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Byrd</surname>
                      <given-names>DW</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Evaluation of cross-calibrated (68)Ge/(68)Ga phantoms for assessing PET/CT measurement bias in oncology imaging for single- and multicenter trials</article-title>
                  <source>Tomography</source>
                  <year>2016</year>
                  <volume>2</volume>
                  <fpage>353</fpage>
                  <lpage>360</lpage>
                  <pub-id pub-id-type="doi">10.18383/j.tom.2016.00205</pub-id>
                  <?supplied-pmid 28066807?>
                  <pub-id pub-id-type="pmid">28066807</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Altazi</surname>
                      <given-names>BA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Reproducibility of F18-FDG PET radiomic features for different cervical tumor segmentation methods, gray-level discretization, and reconstruction algorithms</article-title>
                  <source>J. Appl. Clin. Med. Phys.</source>
                  <year>2017</year>
                  <volume>18</volume>
                  <fpage>32</fpage>
                  <lpage>48</lpage>
                  <pub-id pub-id-type="doi">10.1002/acm2.12170</pub-id>
                  <?supplied-pmid 28891217?>
                  <pub-id pub-id-type="pmid">28891217</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Traverso</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Wee</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Dekker</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Gillies</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Repeatability and reproducibility of radiomic features: A systematic review</article-title>
                  <source>Int. J. Radiat. Oncol. Biol. Phys.</source>
                  <year>2018</year>
                  <volume>102</volume>
                  <fpage>1143</fpage>
                  <lpage>1158</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ijrobp.2018.05.053</pub-id>
                  <?supplied-pmid 30170872?>
                  <pub-id pub-id-type="pmid">30170872</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Leijenaar</surname>
                      <given-names>RT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability</article-title>
                  <source>Acta Oncol.</source>
                  <year>2013</year>
                  <volume>52</volume>
                  <fpage>1391</fpage>
                  <lpage>1397</lpage>
                  <pub-id pub-id-type="doi">10.3109/0284186X.2013.812798</pub-id>
                  <?supplied-pmid 24047337?>
                  <pub-id pub-id-type="pmid">24047337</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wahl</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Jacene</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Kasamon</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Lodge</surname>
                      <given-names>MA</given-names>
                    </name>
                  </person-group>
                  <article-title>From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors</article-title>
                  <source>J. Nucl. Med.</source>
                  <year>2009</year>
                  <volume>50</volume>
                  <issue>Suppl 1</issue>
                  <fpage>122S</fpage>
                  <lpage>150S</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.108.057307</pub-id>
                  <?supplied-pmid 19403881?>
                  <pub-id pub-id-type="pmid">19403881</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fedorov</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>3D Slicer as an image computing platform for the Quantitative Imaging Network</article-title>
                  <source>Magn. Reson. Imaging</source>
                  <year>2012</year>
                  <volume>30</volume>
                  <fpage>1323</fpage>
                  <lpage>1341</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.mri.2012.05.001</pub-id>
                  <?supplied-pmid 22770690?>
                  <pub-id pub-id-type="pmid">22770690</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McNitt-Gray</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Standardization in quantitative imaging: A multicenter comparison of radiomic features from different software packages on digital reference objects and patient data sets</article-title>
                  <source>Tomography</source>
                  <year>2020</year>
                  <volume>6</volume>
                  <fpage>118</fpage>
                  <lpage>128</lpage>
                  <pub-id pub-id-type="doi">10.18383/j.tom.2019.00031</pub-id>
                  <?supplied-pmid 32548288?>
                  <pub-id pub-id-type="pmid">32548288</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van Griethuysen</surname>
                      <given-names>JJM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Computational radiomics system to decode the radiographic phenotype</article-title>
                  <source>Cancer Res.</source>
                  <year>2017</year>
                  <volume>77</volume>
                  <fpage>e104</fpage>
                  <lpage>e107</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0339</pub-id>
                  <?supplied-pmid 29092951?>
                  <pub-id pub-id-type="pmid">29092951</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <mixed-citation publication-type="other">Zwanenburg, A., Leger, S., Vallières, M. &amp; Löck, S. Image biomarker standardisation initiative. arXiv preprint arvXiv:1612.07003 (2016).</mixed-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zwanenburg</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The image biomarker standardization initiative: Standardized quantitative radiomics for high-throughput image-based phenotyping</article-title>
                  <source>Radiology</source>
                  <year>2020</year>
                  <pub-id pub-id-type="doi">10.1148/radiol.2020191145</pub-id>
                  <?supplied-pmid 32154773?>
                  <pub-id pub-id-type="pmid">32154773</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Haralick</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Shanmugam</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Dinstein</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Textural features for image classification</article-title>
                  <source>IEEE Trans. Syst. Man Cybern.</source>
                  <year>1973</year>
                  <volume>SMC-3</volume>
                  <fpage>610</fpage>
                  <lpage>621</lpage>
                  <pub-id pub-id-type="doi">10.1109/TSMC.1973.4309314</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Amadasun</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>King</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Textural features corresponding to textural properties</article-title>
                  <source>IEEE Trans. Syst. Man Cybern.</source>
                  <year>1989</year>
                  <volume>19</volume>
                  <fpage>1264</fpage>
                  <lpage>1274</lpage>
                  <pub-id pub-id-type="doi">10.1109/21.44046</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
